Free Trial Free TrialFree Trial

More results...

Filter by Content types
Market profile databases
Pricing snapshots
Regulatory databases
Product category trackers
Regulatory reports
Market reports
Infographics
Market Snapshots
News analysis
Flavour & nicotine trackers
Filter by Geography
Africa
Asia
Australasia
Central America
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Taiwan Fines coming into force for selling or using e-cigs…
  • United Kingdom ‘Smokefree 2030’ – government promises proposals soon…
  • United States Schumer tells FDA to take strong action against ‘kid-friendly’ Elf Bar…
  • Belgium E-cigarette notification lists updated…
  • United Kingdom Counterfeit e-cigs seized…
  • Italy Ministers plan new administrative procedures for e-cig sales network…
  • Egypt Customs clarifies e-cig tax rates…
  • Bahrain Health ministry oversight extended for nicotine product standards…
  • Bulgaria Finance ministry introduces draft law increasing e-cig taxes…
  • Europe EU member states want more flexible packaging law…
  • Netherlands Inspection finds many stores violate display ban…
  • United States FDA issues MDOs for two menthol Vuse products…
View all
News analysis

Senators urge rejection of PMI reduced risk application after TPSAC findings

Written by || 13th February 2018 || News analysis || Health and science | Policy and Politics | Regulation and Legislation | North America United States

Ten US Senators have urged the FDA to reject PMI's reduced risk application for IQOS following the findings of the independent Tobacco Products Scientific Advisory Committee (TPSAC) ...

Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us

Related contents

Could the TPD allow for reduced-risk claims?
FDA committee rejects two IQOS MRTP claims, approves one
Has Reuters’ IQOS investigation crucially dented PMI’s reputation?